XOMA Corporation (XOMA)
| Previous close | 26.09 |
| Open | 26.14 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 25.80 - 26.14 |
| 52-week range | 13.48 - 27.00 |
| Volume | |
| Avg. volume | 18,988 |
| Market cap | 300.183M |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.04 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | 2.16 (8.26%) |
| Ex-dividend date | 02 Apr 2024 |
| 1y target est | N/A |
PR NewswireActym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical eval
Simply Wall St.XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...
GlobeNewswireXOMA Corporation Announces Closing of Tender Offer
Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value RightEMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ: KN
